EUROIMMUN Showcases Immunoassay Testing Products at MEDICA 2019
|
By LabMedica International staff writers Posted on 19 Nov 2019 |

Image: EUROBlotOne (Photo courtesy of EUROIMMUN)
EUROIMMUN AG (Lübeck, Germany) showcased its intelligent automation solutions for processing and evaluation of test systems, such as ELISA, indirect immunofluorescence tests, immunoblots, molecular genetic detection, and chemiluminescence immunoassays, at MEDICA 2019, which took place from 18-21 November in Düsseldorf, Germany. The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. More than 5,000 exhibitors from 70 countries presented their newest products and ideas at MEDICA which also drew 120,000 trade visitors from over 170 countries.
EUROIMMUN produces test systems for the laboratory diagnosis of autoimmune and infectious diseases, allergies, and for gene analyses. In the foreground are test systems for the determination of antibodies, but also of antigens and genetic markers in patient samples. They are based on both immunohisto-chemical and biochemical methods, such as indirect immunofluorescence, microtiter ELISAs and different blot techniques (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB), and techniques from molecular biology (microarray).
At MEDICA 2019, EUROIMMUN showcased the EUROLabWorkstations for ELISA and IIFT, the company’s high-throughput instruments for fully automated processing for large sample volumes; MERGITE!, its stand-alone device for washing of IIFT slides that guarantees important throughput by parallel washing of up to 50 substrate fields; and the EUROPattern Microscope Live for live microscopy via touch screen and fully automated image recording in less than two seconds per image.
EUROIMMUN also highlighted its EUROBlotOne, an instrument for fully automated processing of immunoblots, at this year’s MEDICA. EUROBlotOne automatically processes immunoblot tests – from sample identification to the final result and features integrated barcode identification to ensure that the correct samples are pipetted. Autoimmune diagnostics, infectious serology and allergology can all be performed on one system which features several innovative multi-parameter tests. It also has a high walk-away capacity with the capability for analyzing up to 44 samples in one run.
EUROIMMUN showcased the PreNat II for efficient extraction of nucleic acids and preparation of PCR reactions as well as the EUROArrayScanner for evaluation of its molecular genetic tests. Also on display at the event was the RA Analyzer 10, a compact random-access instrument from EUROIMMUN for complete automation of chemiluminescence immunoassays.
EUROIMMUN also presented its new test systems, such as the Aspergillus Antigen ELISA (detection of galactomannoprotein for the diagnosis of invasive aspergillosis), the EUROArray Dermatomycosis (microarray for complete identification of the most important pathogens causing fungal infection of the skin), and the company’s growing portfolio of its new bead-based ChLIAs for use on random-access devices.
Related Links:
EUROIMMUN
EUROIMMUN produces test systems for the laboratory diagnosis of autoimmune and infectious diseases, allergies, and for gene analyses. In the foreground are test systems for the determination of antibodies, but also of antigens and genetic markers in patient samples. They are based on both immunohisto-chemical and biochemical methods, such as indirect immunofluorescence, microtiter ELISAs and different blot techniques (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB), and techniques from molecular biology (microarray).
At MEDICA 2019, EUROIMMUN showcased the EUROLabWorkstations for ELISA and IIFT, the company’s high-throughput instruments for fully automated processing for large sample volumes; MERGITE!, its stand-alone device for washing of IIFT slides that guarantees important throughput by parallel washing of up to 50 substrate fields; and the EUROPattern Microscope Live for live microscopy via touch screen and fully automated image recording in less than two seconds per image.
EUROIMMUN also highlighted its EUROBlotOne, an instrument for fully automated processing of immunoblots, at this year’s MEDICA. EUROBlotOne automatically processes immunoblot tests – from sample identification to the final result and features integrated barcode identification to ensure that the correct samples are pipetted. Autoimmune diagnostics, infectious serology and allergology can all be performed on one system which features several innovative multi-parameter tests. It also has a high walk-away capacity with the capability for analyzing up to 44 samples in one run.
EUROIMMUN showcased the PreNat II for efficient extraction of nucleic acids and preparation of PCR reactions as well as the EUROArrayScanner for evaluation of its molecular genetic tests. Also on display at the event was the RA Analyzer 10, a compact random-access instrument from EUROIMMUN for complete automation of chemiluminescence immunoassays.
EUROIMMUN also presented its new test systems, such as the Aspergillus Antigen ELISA (detection of galactomannoprotein for the diagnosis of invasive aspergillosis), the EUROArray Dermatomycosis (microarray for complete identification of the most important pathogens causing fungal infection of the skin), and the company’s growing portfolio of its new bead-based ChLIAs for use on random-access devices.
Related Links:
EUROIMMUN
Latest Medica 2019 News
- Mast Group Introduces New MAST CARBA PAcE for Rapid Carbapenemase Detection
- DRG Instruments Demonstrates DRG:HYBRID-XL Fully Automated Lab Analyzer
- Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer
- Alifax S.r.l. Highlights First Automated System for Bacterial Culture and Susceptibility Testing
- Erba Mannheim Showcases New Launches at MEDICA 2019
- Diconex S.A. Exhibits InCCA Intelligent Clinical Chemistry Analyzer at MEDICA 2019
- Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019
- DYNEX Demonstrates DYNABLOT Automatic Analyzer for Immunoblot and Westernblot Methods
- Systec Launches New and Improved HX-150 Autoclave at MEDICA 2019
- TaiDoc Showcases Multi-Parameter Monitoring Systems and Advanced Devices
- IDS Exhibits Next Generation Automated Immunoanalyzer IDS-i10 at MEDICA 2019
- JEOL Ltd. Introduces BioMajesty Series of Clinical Chemistry Analyzers at MEDICA 2019
- EKF Diagnostics Showcases Full Product Range at MEDICA 2019
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








